OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials
Gil Yosipovitch, Nicholas Mollanazar, Sonja Ständer, et al.
Nature Medicine (2023) Vol. 29, Iss. 5, pp. 1180-1190
Open Access | Times Cited: 116
Gil Yosipovitch, Nicholas Mollanazar, Sonja Ständer, et al.
Nature Medicine (2023) Vol. 29, Iss. 5, pp. 1180-1190
Open Access | Times Cited: 116
Showing 1-25 of 116 citing articles:
Type 2 chronic inflammatory diseases: targets, therapies and unmet needs
Pavel Kolkhir, Cezmi A. Akdiş, Mübeccel Akdiş, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 9, pp. 743-767
Closed Access | Times Cited: 67
Pavel Kolkhir, Cezmi A. Akdiş, Mübeccel Akdiş, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 9, pp. 743-767
Closed Access | Times Cited: 67
Chronic Pruritus
Daniel Butler, Timothy G. Berger, Sarina B. Elmariah, et al.
JAMA (2024) Vol. 331, Iss. 24, pp. 2114-2114
Closed Access | Times Cited: 21
Daniel Butler, Timothy G. Berger, Sarina B. Elmariah, et al.
JAMA (2024) Vol. 331, Iss. 24, pp. 2114-2114
Closed Access | Times Cited: 21
Neuroimmune interplay during type 2 inflammation: Symptoms, mechanisms, and therapeutic targets in atopic diseases
Brian Kim, Marc E. Rothenberg, Xin Sun, et al.
Journal of Allergy and Clinical Immunology (2023) Vol. 153, Iss. 4, pp. 879-893
Open Access | Times Cited: 35
Brian Kim, Marc E. Rothenberg, Xin Sun, et al.
Journal of Allergy and Clinical Immunology (2023) Vol. 153, Iss. 4, pp. 879-893
Open Access | Times Cited: 35
Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments
Svenja Müller, Claudia Zeidler, Sonja Ständer
American Journal of Clinical Dermatology (2023) Vol. 25, Iss. 1, pp. 15-33
Open Access | Times Cited: 29
Svenja Müller, Claudia Zeidler, Sonja Ständer
American Journal of Clinical Dermatology (2023) Vol. 25, Iss. 1, pp. 15-33
Open Access | Times Cited: 29
Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry
Junfen Zhang, Celeste M. Boesjes, Laura Loman, et al.
Journal of the American Academy of Dermatology (2024) Vol. 91, Iss. 2, pp. 300-311
Open Access | Times Cited: 11
Junfen Zhang, Celeste M. Boesjes, Laura Loman, et al.
Journal of the American Academy of Dermatology (2024) Vol. 91, Iss. 2, pp. 300-311
Open Access | Times Cited: 11
Efficacy and Safety of Abrocitinib in Prurigo Nodularis and Chronic Pruritus of Unknown Origin
Shawn G. Kwatra, Zachary A. Bordeaux, Varsha Parthasarathy, et al.
JAMA Dermatology (2024) Vol. 160, Iss. 7, pp. 717-717
Open Access | Times Cited: 10
Shawn G. Kwatra, Zachary A. Bordeaux, Varsha Parthasarathy, et al.
JAMA Dermatology (2024) Vol. 160, Iss. 7, pp. 717-717
Open Access | Times Cited: 10
Prurigo nodularis: new insights into pathogenesis and novel therapeutics
Viviane Liao, Hannah Cornman, Emily Ma, et al.
British Journal of Dermatology (2024) Vol. 190, Iss. 6, pp. 798-810
Closed Access | Times Cited: 8
Viviane Liao, Hannah Cornman, Emily Ma, et al.
British Journal of Dermatology (2024) Vol. 190, Iss. 6, pp. 798-810
Closed Access | Times Cited: 8
Increased cardiovascular risks and mortality in prurigo nodularis: a global cohort study
Henning Olbrich, Khalaf Kridin, Gema Hernández, et al.
EBioMedicine (2024) Vol. 103, pp. 105123-105123
Open Access | Times Cited: 8
Henning Olbrich, Khalaf Kridin, Gema Hernández, et al.
EBioMedicine (2024) Vol. 103, pp. 105123-105123
Open Access | Times Cited: 8
Comparative safety of oral Janus kinase inhibitors and dupilumab in patients with atopic dermatitis: a population-based cohort study
Serena Yun‐Chen Tsai, Wanda Phipatanakul, Elena B. Hawryluk, et al.
Journal of Allergy and Clinical Immunology (2024) Vol. 154, Iss. 5, pp. 1195-1203.e3
Closed Access | Times Cited: 8
Serena Yun‐Chen Tsai, Wanda Phipatanakul, Elena B. Hawryluk, et al.
Journal of Allergy and Clinical Immunology (2024) Vol. 154, Iss. 5, pp. 1195-1203.e3
Closed Access | Times Cited: 8
Effectiveness and Safety of Dupilumab for Prurigo Nodularis in China: A Multicentric and Observational Study
Zuotao Zhao, Xiaoting Song, Yuanyuan Shang, et al.
Allergy (2025)
Open Access | Times Cited: 1
Zuotao Zhao, Xiaoting Song, Yuanyuan Shang, et al.
Allergy (2025)
Open Access | Times Cited: 1
Neuroimmune mechanisms of type 2 inflammation in the skin and lung
Masato Tamari, Aaron Ver Heul
Allergology International (2025)
Open Access | Times Cited: 1
Masato Tamari, Aaron Ver Heul
Allergology International (2025)
Open Access | Times Cited: 1
Single-cell profiling of prurigo nodularis demonstrates immune-stromal crosstalk driving profibrotic responses and reversal with nemolizumab
Feiyang Ma, Mehrnaz Gharaee‐Kermani, Lam C. Tsoi, et al.
Journal of Allergy and Clinical Immunology (2023) Vol. 153, Iss. 1, pp. 146-160
Open Access | Times Cited: 20
Feiyang Ma, Mehrnaz Gharaee‐Kermani, Lam C. Tsoi, et al.
Journal of Allergy and Clinical Immunology (2023) Vol. 153, Iss. 1, pp. 146-160
Open Access | Times Cited: 20
Molecular mechanisms of pruritus in prurigo nodularis
Yixin Shao, Duoqin Wang, Yiqi Zhu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 17
Yixin Shao, Duoqin Wang, Yiqi Zhu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 17
“Input/output cytokines” in epidermal keratinocytes and the involvement in inflammatory skin diseases
Shin Morizane, Tomoyuki Mukai, Ko Sunagawa, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 16
Shin Morizane, Tomoyuki Mukai, Ko Sunagawa, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 16
Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT
Dédée F. Murrell, P. Joly, Victoria P. Werth, et al.
Advances in Therapy (2024) Vol. 41, Iss. 7, pp. 2991-3002
Open Access | Times Cited: 5
Dédée F. Murrell, P. Joly, Victoria P. Werth, et al.
Advances in Therapy (2024) Vol. 41, Iss. 7, pp. 2991-3002
Open Access | Times Cited: 5
Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II/III clinical study in patients aged ≥ 13 years
Hiroo Yokozeki, Hiroyuki Murota, Takayo Matsumura, et al.
British Journal of Dermatology (2024) Vol. 191, Iss. 2, pp. 200-208
Open Access | Times Cited: 5
Hiroo Yokozeki, Hiroyuki Murota, Takayo Matsumura, et al.
British Journal of Dermatology (2024) Vol. 191, Iss. 2, pp. 200-208
Open Access | Times Cited: 5
Stapokibart (CM310) targets IL-4Rα for the treatment of type 2 inflammation
Wei Liu, Yan Zhao, Yanyun He, et al.
iScience (2024) Vol. 27, Iss. 9, pp. 110721-110721
Open Access | Times Cited: 5
Wei Liu, Yan Zhao, Yanyun He, et al.
iScience (2024) Vol. 27, Iss. 9, pp. 110721-110721
Open Access | Times Cited: 5
Emerging concepts in neuropathic and neurogenic itch
Kelsey L. Auyeung, Brian Kim
Annals of Allergy Asthma & Immunology (2023) Vol. 131, Iss. 5, pp. 561-566
Open Access | Times Cited: 12
Kelsey L. Auyeung, Brian Kim
Annals of Allergy Asthma & Immunology (2023) Vol. 131, Iss. 5, pp. 561-566
Open Access | Times Cited: 12
A critical evaluation of nemolizumab for prurigo nodularis
Sarah G Brooks, Gil Yosipovitch
Expert Review of Clinical Immunology (2024) Vol. 20, Iss. 6, pp. 577-587
Closed Access | Times Cited: 4
Sarah G Brooks, Gil Yosipovitch
Expert Review of Clinical Immunology (2024) Vol. 20, Iss. 6, pp. 577-587
Closed Access | Times Cited: 4
Development and Validation of a Patient-Reported Outcome Measure to Assess Disease Control in Chronic Prurigo
Martin Metz, Claudia Zeidler, Tomasz Hawro, et al.
JAMA Dermatology (2024) Vol. 160, Iss. 2, pp. 187-187
Closed Access | Times Cited: 4
Martin Metz, Claudia Zeidler, Tomasz Hawro, et al.
JAMA Dermatology (2024) Vol. 160, Iss. 2, pp. 187-187
Closed Access | Times Cited: 4
Long‐term therapeutic response to dupilumab in patients affected by prurigo nodularis: A real‐world retrospective study
Andrea Chiricozzi, Niccolò Gori, Elena Ippoliti, et al.
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 10
Closed Access | Times Cited: 4
Andrea Chiricozzi, Niccolò Gori, Elena Ippoliti, et al.
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 10
Closed Access | Times Cited: 4
Prevalence of Metabolic Diseases in Patients With Prurigo Nodularis: A Systematic Review and Meta‐Analysis
Natalia Chalupczak, Michael E. DeVine, Christy H. Chang, et al.
International Journal of Dermatology (2025)
Closed Access
Natalia Chalupczak, Michael E. DeVine, Christy H. Chang, et al.
International Journal of Dermatology (2025)
Closed Access
Reductive Adjuvant Nanosystem for Alleviated Atopic Dermatitis Syndromes
Yichao Lu, Xinyu Shan, Jiaxin Huang, et al.
ACS Nano (2025)
Closed Access
Yichao Lu, Xinyu Shan, Jiaxin Huang, et al.
ACS Nano (2025)
Closed Access
Thymus and activation-regulated chemokine (CCL17) as a clinical biomarker in atopic dermatitis: significance and limitations in the new treatment era
Yoko Kataoka
Frontiers in Allergy (2025) Vol. 5
Open Access
Yoko Kataoka
Frontiers in Allergy (2025) Vol. 5
Open Access
Efficacy and Safety of Dupilumab Across Different Th2-Type-Mediated Diseases: A Real-Life Preliminary Experience
Ciro Romano, Domenico Cozzolino, Maria Elena Corona, et al.
Biologics (2025) Vol. 5, Iss. 1, pp. 3-3
Open Access
Ciro Romano, Domenico Cozzolino, Maria Elena Corona, et al.
Biologics (2025) Vol. 5, Iss. 1, pp. 3-3
Open Access
